Androgen News and Research

RSS

Why protein powders can secretly cause doping bans

Adulterated protein supplements can lead to unintentional doping. This review outlines detection strategies and protective measures for athletes and clinicians.

9 Oct 2025

New drug combination could delay the progression of advanced prostate cancer

A new drug combination could significantly delay the progression of a life-threatening form of prostate cancer in men with specific genetic mutations, finds a major international trial led by UCL researchers.

7 Oct 2025

New ASPIRE trial tests chemotherapy combination for advanced prostate cancer

The Alliance for Clinical Trials in Oncology has launched the ASPIRE trial-a large-scale, Phase III clinical study investigating whether adding chemotherapy to current standard treatments can extend survival for men living with advanced prostate cancer.

6 Oct 2025

Gene expression test identifies prostate cancer patients who benefit from hormone therapy

A new randomized study finds that a lab test that reads tumor genes can identify which patients with recurrent prostate cancer will benefit from adding hormone therapy to radiation after surgery - the first predictive biomarker in this setting.

29 Sep 2025

Combining radiopharmaceuticals with targeted radiation improves progression-free survival in prostate cancer patients

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a radiopharmaceutical drug before targeted radiation, compared with radiation alone.

29 Sep 2025

UCLA presents advances in radiation therapy at ASTRO 2025

Physicians and scientists from the UCLA Health Jonsson Comprehensive Cancer Center will share the latest research and clinical trial results at the 2025 American Society for Radiation Oncology (ASTRO) Annual Meeting, including studies on targeted radioactive therapy for recurrent prostate cancer, new approaches to stereotactic body radiation for prostate and head and neck cancers, advances in MRI- and 5DCT-guided imaging for more precise treatments, and innovations in patient-focused cancer education.

26 Sep 2025

Genomic testing speeds patient accrual in high-risk prostate cancer trial

The NRG Oncology NRG-GU009 (PREDICT-RT) study evaluating intensified and de-intensified concurrent radiation regimens based on the genomic risk of patients with high-risk prostate cancer completed accrual and met its accrual milestone of 2,478 patients approximately two years earlier than the trial's anticipated accrual completion date.

19 Sep 2025

Long COVID linked to heavier periods and symptom flare-ups during menstruation

Researchers found that long COVID is linked to heavier, longer, and more irregular bleeding without disrupting ovulation. Symptom severity also peaks around menstruation, likely driven by hormonal and immune changes.

17 Sep 2025

Study links hysterectomy and bilateral oophorectomy to higher stroke risk

Given the seriousness and increased frequency of strokes, many studies have been conducted to assess the relationship between hysterectomy and/or bilateral oophorectomy and the risk of stroke with varying results.

3 Sep 2025

Androgen deprivation therapy lowers satisfaction after penile prosthesis surgery

Prostate cancer is the most common malignancy among men, with over 160,000 new cases diagnosed annually in the United States.

1 Sep 2025

Exploring testosterone's influence on cardiovascular, metabolic, reproductive, and mental health

For decades, testosterone has been recognized as the primary driver of male reproductive development and secondary sex characteristics.

1 Sep 2025

Molecular profiling identifies prostate cancer patients who benefit most from chemotherapy

Testing the molecular profile of tumors identifies which patients with advanced prostate cancer are more likely to benefit from chemotherapy and live longer, sparing patients less likely to benefit from unpleasant side effects, according to a new study led by UCL researchers.

28 Aug 2025

RSPO2 gene identified as key driver in metastatic prostate cancer

A new research paper was published in Volume 16 of Oncotarget on July 25, 2025, titled "Dissecting the functional differences and clinical features of R-spondin family members in metastatic prostate cancer."

11 Aug 2025

HOXB13 emerges as a context-dependent regulator in cancer biology

HOXB13, a B-class homeobox transcription factor, sits at the hub of developmental gene networks yet has emerged as a double-edged sword in human cancer.

5 Aug 2025

Starfish compound overcomes drug resistance in prostate cancer models

Researchers identified that triterpene glycosides from the starfish Solaster pacificus can kill drug-resistant prostate cancer cells in vitro by bypassing common resistance pathways. CuC1 showed synergy with existing chemotherapies, though with only moderate selectivity for cancer cells.

5 Aug 2025

Study identifies why some prostate cancers fail to respond to treatment

A new study from University of Michigan Rogel Cancer Center researchers identifies a cellular signature that explains why about one-third of prostate cancers respond especially poorly to treatment.

8 Jul 2025

Study reveals how FOXA1 mutations drive prostate cancer and therapy resistance

A new study from the University of Michigan Rogel Health Cancer Center, published in Science, sheds light on how two distinct classes of mutations in the FOXA1 gene-commonly altered in prostate cancer-drive tumor initiation formation and therapeutic resistance.

26 Jun 2025